The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Questcor Pharmaceuticals's revenues will grow 50.6% and EPS will increase 44.6%.
The average estimate for revenue is $169.4 million. On the bottom line, the average EPS estimate is $0.94.
Last quarter, Questcor Pharmaceuticals booked revenue of $135.1 million. GAAP reported sales were 41% higher than the prior-year quarter's $96.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.65. GAAP EPS of $0.65 for Q1 were 12% higher than the prior-year quarter's $0.58 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 88.0%, 620 basis points worse than the prior-year quarter. Operating margin was 43.9%, much worse than the prior-year quarter. Net margin was 28.9%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $662.5 million. The average EPS estimate is $3.64.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 497 members out of 550 rating the stock outperform, and 53 members rating it underperform. Among 151 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 127 give Questcor Pharmaceuticals a green thumbs-up, and 24 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is outperform, with an average price target of $45.38.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Questcor Pharmaceuticals. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Questcor Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Stocks Near 52-Week Highs Worth Selling
Are these three stocks sells or belles? You be the judge!
Growth in Acthar Gel Pushes Questcor's Profits Up by 84% in Q1
The expanded use of Acthar Gel sends Questcor's sales and profits soaring in the first quarter.
5 Unlikely Companies Bucking the Biotech Sell-Off
The SPDR S&P Biotech ETF is down 22.4% over the trailing month, but these five biotech stocks are all up. What's their secret?